Subcortical shape alterations in major depressive disorder: Findings from the ENIGMA major depressive disorder working group

Ho TC, Gutman B, Pozzi E, Grabe HJ, Hosten N, Wittfeld K, Völzke H, Baune B, Dannlowski U, Förster K, Grotegerd D, Redlich R, Jansen A, Kircher T, Krug A, Meinert S, Nenadic I, Opel N, Dinga R, Veltman DJ, Schnell K, Veer I, Walter H, Gotlib IH, Sacchet MD, Aleman A, Groenewold NA, Stein DJ, Li M, Walter M, Ching CRK, Jahanshad N, Ragothaman A, Isaev D, Zavaliangos-Petropulu A, Thompson PM, Sämann PG, Schmaal L

Abstract

Alterations in regional subcortical brain volumes have been investigated as part of the efforts of an international consortium, ENIGMA, to identify reliable neural correlates of major depressive disorder (MDD). Given that subcortical structures are comprised of distinct subfields, we sought to build significantly from prior work by precisely mapping localized MDD-related differences in subcortical regions using shape analysis. In this meta-analysis of subcortical shape from the ENIGMA-MDD working group, we compared 1,781 patients with MDD and 2,953 healthy controls (CTL) on individual measures of shape metrics (thickness and surface area) on the surface of seven bilateral subcortical structures: nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus. Harmonized data processing and statistical analyses were conducted locally at each site, and findings were aggregated by meta-analysis. Relative to CTL, patients with adolescent-onset MDD (≤ 21 years) had lower thickness and surface area of the subiculum, cornu ammonis (CA) 1 of the hippocampus and basolateral amygdala (Cohen's d = -0.164 to -0.180). Relative to first-episode MDD, recurrent MDD patients had lower thickness and surface area in the CA1 of the hippocampus and the basolateral amygdala (Cohen's d = -0.173 to -0.184). Our results suggest that previously reported MDD-associated volumetric differences may be localized to specific subfields of these structures that have been shown to be sensitive to the effects of stress, with important implications for mapping treatments to patients based on specific neural targets and key clinical features.